Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: J Immunol. 2021 Apr 7;206(9):2122–2134. doi: 10.4049/jimmunol.2100018

Figure 1. Prime-boost vaccination with RSVNanoVax protects against RSV-induced weight loss and pulmonary dysfunction.

Figure 1.

BALB/c mice were primed i.n. on day 0 and boosted with 500 μg on day 28. All mice were challenged with 4.8 × 106 PFU RSV-A2 on day 56 (A), day 100 (B), or 6 months (C) post-prime and assessed for weight loss and pulmonary dysfunction as measured by baseline changes in Penh and EF50. Asterisks represent significance between no vaccine and RSVNanoVax and pound symbols represent significance between CpGNanoVax and RSVNanoVax as determined by 2-way ANOVA with a Dunnett’s post hoc test. */# p<0.05, **/## p<0.01, ***/### p<0.001. No vaccine mice were administered PBS i.n. at both the prime and boost. Data represent mean ± SEM of 2–3 independent experiments (n=8–12).